 BOULDER, Colo., Dec. 11, 2019 GLOBE NEWSWIRE -- miRagen Therapeutics, Inc. MGEN, a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced a series of strategic changes across its business that are intended to reallocate its existing capital to deliver important milestones in 2020. 